

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 December 2021 (16.12.2021)



(10) International Publication Number
WO 2021/252644 A1

(51) International Patent Classification:

C07D 207/263 (2006.01) C07D 513/04 (2006.01)
C07D 235/24 (2006.01) C07D 209/34 (2006.01)
C07D 403/12 (2006.01) C07F 7/08 (2006.01)
C07D 471/04 (2006.01) C07D 521/00 (2006.01)
C07D 417/14 (2006.01) A61P 31/12 (2006.01)
C07D 403/14 (2006.01) A61K 31/40 (2006.01)
C07D 401/14 (2006.01) A61K 31/4184 (2006.01)
C07D 401/12 (2006.01) A61K 31/438 (2006.01)
C07D 405/14 (2006.01) A61K 31/45 (2006.01)
C07D 487/10 (2006.01) A61K 31/454 (2006.01)
C07D 471/10 (2006.01) C07K 14/165 (2006.01)
C07D 413/14 (2006.01) C12N 9/50 (2006.01)
C07D 491/107 (2006.01) C12N 9/99 (2006.01)

(74) Agent: KAVANAUGH, Theresa C. et al.; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept./7Th Fl, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2021/036638

(22) International Filing Date:

09 June 2021 (09.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/036,866	09 June 2020 (09.06.2020)	US
63/039,297	15 June 2020 (15.06.2020)	US
63/067,669	19 August 2020 (19.08.2020)	US
63/091,630	14 October 2020 (14.10.2020)	US
63/129,018	22 December 2020 (22.12.2020)	US
63/171,675	07 April 2021 (07.04.2021)	US
63/172,478	08 April 2021 (08.04.2021)	US
63/173,146	09 April 2021 (09.04.2021)	US
63/179,128	23 April 2021 (23.04.2021)	US
63/195,460	01 June 2021 (01.06.2021)	US

(71) Applicant: PARDES BIOSCIENCES, INC. [US/US]; 2173 Salk Ave., Suite 250, PMB#052, Carlsbad, California 92008 (US).

(72) Inventors: ARNOLD, Lee D.; 7982 Camino de Arriba, Rancho Santa Fe, California 92067-0012 (US). JENNINGS, Andy; 7951 Canary Way, San Diego, California 92123 (US). KEUNG, Walter; 536 Forrest Bluff, Encinitas, California 92024 (US).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF



(II)

(57) Abstract: The disclosure provides compounds of formula II with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease. Formula II

WO 2021/252644 A1